Clinical disclaimer: This article is educational and does not constitute personal medical advice. If you take medication affected by weight change, or have type 2 diabetes, involve your clinician before making any changes. Never stop medication abruptly without clinical supervision.

Why the conversation matters

Most patients who stop Wegovy do so without a structured clinical conversation. The prescription ends, they stop injecting, and they manage whatever happens next independently. This is not how other significant medication changes are handled — and it produces predictably poor outcomes. The questions below are not bureaucratic; each one addresses a clinical variable that changes the risk picture.

Do my blood pressure medications need reviewing?

This is the question most likely to be missed. If you have lost significant weight on Wegovy — 10% or more — your blood pressure may have fallen enough to make existing antihypertensives excessive. Stopping Wegovy changes the trajectory again as weight potentially returns. Ask your doctor for a blood pressure check before stopping and agree a monitoring plan for the transition. [1] See blood pressure after weight loss for more detail.

What happens to my glucose control when I stop?

If you have type 2 diabetes or pre-diabetes, Wegovy's GLP-1 mechanism is affecting your glucose alongside weight. Stopping will worsen glucose control to some degree. Before stopping, ask: what is my current HbA1c? Do I need adjusted monitoring after stopping? Does my diabetes medication list need reviewing? If you are on a sulphonylurea or insulin alongside Wegovy, the risk picture when Wegovy stops is different from a patient on metformin alone. [2]

Is there a clinical reason to stop now, or is this a preference?

This is worth asking yourself as much as your doctor. Common reasons people stop Wegovy: reached target weight; cost; side effects; supply issues; pregnancy planning; surgical procedure. Each of these has different clinical implications. Stopping because of a side effect warrants a discussion about whether dose reduction might resolve it. Stopping for surgery warrants a specific peri-operative plan. Stopping because of cost is a practical constraint — but a conversation about whether a lower maintenance dose might be sustainable is worth having.

What should I monitor after stopping, and for how long?

Ask for specifics, not vague reassurance. A useful monitoring plan after stopping Wegovy includes: daily weight trend monitoring for at least eight weeks; blood pressure checks at weeks two, four, and eight if on antihypertensives; glucose monitoring if diabetic or pre-diabetic; and a clear threshold at which you return for review. "Come back if you are worried" is not a monitoring plan. [3]

Should I taper or stop abruptly?

Your doctor's answer to this should be honest about the evidence: there is no RCT comparing tapering to planned stopping. Tapering is common practice and may make the appetite transition slightly more gradual, but it is not evidenced as producing better long-term outcomes. The more important question is whether the stopping plan is complete — not exactly how the final dose reduction happens. See should I taper Mounjaro or stop suddenly? for more detail.

What is my plan if I regain significant weight?

Ask for a specific answer to this before stopping. The answer should include: a weight threshold (not just "if you're not happy"), a timeline, and a clear action — whether that is clinical review, restart of medication, or adjustment of other treatment. NICE guidance acknowledges ongoing or restarted treatment is appropriate for patients who meet clinical criteria. [4] "We'll deal with it if it happens" is not adequate for a predictable outcome.

Are there any contraindications to restarting if needed?

If restarting might be relevant in future, it is worth knowing now whether there are clinical reasons that would complicate restarting — previous pancreatitis, thyroid history, or planned procedures. This is planning, not pessimism.

What does a proper GLP-1 exit review look like?

A structured GLP-1 Exit Strategy Review covers: current weight, waist, dose history, indication, reason for stopping, blood pressure, medication list, diabetes status, HbA1c where relevant, lipids, protein intake, resistance training, alcohol pattern, and a written 12-week plan. If your current clinical setting cannot offer this, a private clinical review is a reasonable option.

FAQ

What should I ask my doctor before stopping Wegovy?
The most important questions: Does my blood pressure medication need reviewing given my weight loss? What happens to my glucose control when I stop (if you have diabetes)? What should I monitor, and for how long? What is the plan if I regain significant weight? These are clinical questions with specific answers — not questions that should be met with vague reassurance.
Will my GP review my medications when I stop Wegovy?
Not automatically. Most GPs do not proactively review antihypertensive or diabetes medication when a patient stops a weight-loss injection, unless the patient raises it. You may need to ask explicitly for a blood pressure check and medication review as part of the stopping conversation.
Should I have a blood test before stopping Wegovy?
Clinically useful tests before stopping: HbA1c if you have diabetes or pre-diabetes, fasting lipids if cardiovascular risk is part of the picture, and kidney function if there is any known kidney disease. These give a baseline against which to measure change after stopping.
Can I stop Wegovy without telling my doctor?
Pharmacologically, yes — there is no dangerous withdrawal syndrome. Clinically, it depends on your situation. If you have type 2 diabetes, take insulin or sulphonylureas, or are on blood pressure medication, stopping without clinical review increases risk. For otherwise healthy patients using Wegovy for weight management alone, the risk is lower — but a plan is still better than no plan.
What is a GLP-1 Exit Strategy Review?
A structured private clinical review covering your full medication picture, metabolic markers, weight and waist history, and producing a written 12-week stopping plan. It is designed for patients stopping GLP-1 medication who want a clinical assessment of the transition rather than managing it alone.

References

  1. NICE. Hypertension in adults: diagnosis and management. NG136. 2023.
  2. NICE. Type 2 diabetes in adults: management. NG28. 2024.
  3. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: STEP 1 extension. Diabetes Obes Metab. 2022.
  4. NICE. Overweight and obesity management. NG246. 2025.